56 completed. 56 Phase 2, 6 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 56 | Completed 56 |
| Phase 1 | 6 | Completed 6 |
| Phase 3 | 3 | Completed 3 |
Follow Gallbladder Neoplasms: new trials by email Literature Review of Gallbladder Neoplasms trials Research Report on Gallbladder Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Completed | Arvinas Inc. | 76 | 2025-05-29 | 2026-11-17 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer Durvalumab, Tremelimumab, Capecitabine - Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 40 | 2022-05-23 | 2025-05-01 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 84 | 2022-04-13 | 2025-06-12 |
| MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib - Uterine Cervical Neoplasms, Endometrial Neoplasms | Phase 2 | Completed | Merck Sharp & Dohme LLC | 611 | 2021-09-16 | 2026-09-28 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 203 | 2021-03-14 | 2024-04-26 |
| A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers ZW25 (Zanidatamab) - HER2-amplified Biliary Tract Cancers | Phase 2 | Completed | Jazz Pharmaceuticals | 87 | 2020-10-01 | 2025-09-15 |
| A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL) - Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms | Phase 1 / Phase 2 | Completed | Intima Bioscience, Inc. | 23 | 2020-05-15 | 2026-02-23 |
| Pembrolizumab in Biliary Tract Cancer Pembrolizumab, Cisplatin, Gemcitabine - Biliary Tract Cancer, Metastatic Cancer | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 50 | 2020-01-07 | 2023-11-03 |
| Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer Irinotecan, Irinotecan Hydrochloride, Trifluridine and Tipiracil Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Completed | Mayo Clinic | 28 | 2019-10-18 | 2023-08-09 |
| M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) M7824 - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 159 | 2019-03-26 | 2023-10-25 |
| Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients Durvalumab, Gemcitabine, Cisplatin - Cholangiocarcinoma, Gall Bladder Carcinoma | Phase 2 | Completed | AIO-Studien-gGmbH | 128 | 2018-05-02 | 2023-06-15 |
| Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Atezolizumab, Biopsy, Biospecimen Collection - Gallbladder Carcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2018-02-08 | 2024-04-05 |
| Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine - Biliary Tract Cancer | Phase 2 | Completed | ASLAN Pharmaceuticals | 62 | 2017-12-19 | 2020-11-19 |
| TAS-102 in Treating Advanced Biliary Tract Cancers Laboratory Biomarker Analysis, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 - Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7 | Phase 2 | Completed | Mayo Clinic | 28 | 2017-10-20 | 2023-06-28 |
| Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine, Placebo (for Varlitinib) - Biliary Tract Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 151 | 2017-07-04 | 2021-08-03 |
| Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine - Biliary Tract Neoplasms, Cholangiocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2017-06-14 | 2021-12-03 |
| Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma Cisplatin, Gemcitabine, Copanlisib - Biliary Carcinoma, Gall Bladder Carcinoma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 24 | 2016-07-05 | 2021-08-04 |
| Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Ramucirumab - Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 61 | 2015-12-29 | 2023-06-15 |
| Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 62 | 2015-04-02 | 2022-02-02 |
Showing 20 of 56. Sign in to see all of them.
Bile Duct Neoplasms (26) · Cholangiocarcinoma (24) · Biliary Tract Neoplasms (14) · Carcinoma, Hepatocellular (12) · Liver Neoplasms (8) · Pancreatic Neoplasms (7) · Stomach Neoplasms (7) · Neoplasm Metastasis (4) · Neoplasms (4) · Colonic Neoplasms (3) · Esophageal Neoplasms (3) · Klatskin Tumor (3) · Thyroid Neoplasms (3) · Triple Negative Breast Neoplasms (3)
Biliary Tract Diseases (56) · Digestive System Diseases (56) · Neoplasms by Site (56) · Digestive System Neoplasms (55) · Gallbladder Diseases (55) · Neoplasms (52) · Biliary Tract Neoplasms (42) · Neoplasms by Histologic Type (35) · Neoplasms, Glandular and Epithelial (35) · Adenocarcinoma (34) · Carcinoma (33) · Bile Duct Diseases (25) · Liver Diseases (16) · Endocrine Gland Neoplasms (10) · Endocrine System Diseases (10)
Gemcitabine (21) · Capecitabine (14) · Cisplatin (9) · Oxaliplatin (8) · Fluorouracil (5) · Bevacizumab (4) · Erlotinib Hydrochloride (4) · Leucovorin (4) · Sorafenib (3) · durvalumab (3) · pembrolizumab (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Carboplatin (2) · Docetaxel (2)
National Cancer Institute (NCI) (11) · Alliance for Clinical Trials in Oncology (3) · M.D. Anderson Cancer Center (3) · ASLAN Pharmaceuticals (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Mayo Clinic (2) · Memorial Sloan Kettering Cancer Center (2) · Roswell Park Cancer Institute (2) · SWOG Cancer Research Network (2) · TransThera Sciences (Nanjing), Inc. (2) · Washington University School of Medicine (2) · AIO-Studien-gGmbH (1) · All India Institute of Medical Sciences (1) · Arvinas Inc. (1) · Copenhagen University Hospital, Rigshospitalet (1)
United States (43) · China (7) · Spain (5) · France (4) · Germany (4) · Italy (4) · South Korea (4) · Canada (3) · Japan (3) · Taiwan (3) · United Kingdom (3) · Chile (2) · Poland (2) · Australia (1) · Colombia (1)
Steven R. Alberts, MD (3) · Amit Mahipal (2) · Anthony El-Khoueiry (2) · Benjamin Tan, M.D. (2) · Tanios Bekaii-Saab (2) · Allyson Ocean (1) · Anders Johnsson, MD, PhD (1) · Aram Hezel, MD (1) · Arndt Vogel, Prof. Dr. (1) · Bruno Chauffert (1) · Dieter Koeberle, MD (1) · Edgar Ben-Josef, MD (1) · Emil Lou, MD, PhD (1) · Gao-jun Teng, MD, PhD (1)
PMID 12794246, PMID 15558814, PMID 18669454, PMID 18669455, PMID 19023677, PMID 19737952, PMID 20662793, PMID 20981545, PMID 21556747, PMID 25241229, PMID 25538178, PMID 25964250, PMID 30998813, PMID 32461347, PMID 33289918, PMID 34907910, PMID 35274717, PMID 36999533, PMID 37276871, PMID 37339254, PMID 38087967, PMID 39114870, PMID 40315882, PMID 40673842
U10CA032102 (4), 2023 (2), N01CM17104 (2), N01CM62201 (2), 2017 (1), 2018 (1), N01CM00070 (1), N01CM62204 (1), N01CM62207 (1), N01CM62209 (1), P30CA008748 (1), P30CA015083 (1), P30CA016058 (1), U01CA062505 (1), U10CA180888 (1)